Besides, the escalating therapy was recommended to the young patients (less than 40 year) with stage I-III and HoR+/HER2- breast cancer due to worse survival, which was consistent with the previous studies [17, 20, 21, 33]. This evidence concerns the gene ERBB2 and breast carcinoma.